证券代码：688607 证券简称：康众医疗 公告编号：2025-036 江苏康众数字医疗科技股份有限公司 关于 2025 年提质增效重回报行动方案 半年度评估报告的公告 江苏康众数字医疗科技股份有限公司（以下简称"康众医疗"或"公司"） 为践行"以投资者为本"的发展理念，维护公司及全体股东利益，基于对公司未 来发展前景的信心，公司于 2025 年 4 月 26 日披露了《关于 2024 年度提质增效 重回报行动方案评估报告暨 2025 年度提质增效重回报行动方案》 （以下简称"行 动方案"）。2025 年上半年度，公司切实履行并持续评估行动方案的具体举措， 现将行动方案的实施效果和 2025 上半年度执行情况的评估报告如下： 一、聚集主营业务，推动企业高质量发展 全面把握国内经济稳步复苏机遇，全面推动经营业务长远稳定发展、不断增强公 司核心竞争力。报告期内，公司实现营业收入 144,883,131.24 元，较上年同期增 长 12.41%，归属于上市公司股东的净利润为-739,398.63 元，因对应收账款计提 坏账准备，导致较上年同期有所减少。2025 年上半年度，公司管理层及全体员 工坚持加快战略推进、技 ...

Core Insights - The report highlights the significant growth in revenue and profitability for various companies in the technology and energy sectors, indicating a positive trend in their respective markets [6][23][15]. Industry Overview - The non-bank financial sector is experiencing a resurgence, with a focus on investment value as half-year reports are being released [5]. - The semiconductor and advanced packaging industries are seeing increased demand, driven by technological advancements and market expansion [8][11]. Company Analysis - **Stone Technology (688169.SH)**: The company reported a revenue of 7.903 billion, a year-on-year increase of 78.96%, but a decline in net profit by 39.55% [6]. - **Jiaocheng Ultrasonic (688392.SH)**: The company experienced a significant improvement in profitability, with a focus on scaling its advanced packaging business [8]. - **Green's Harmonics (688017.SH)**: The company achieved a revenue growth of 45.8% in the first half of 2025, driven by a recovery in the industrial robot market [15]. - **Hongyuan Co., Ltd. (920018.BJ)**: Recognized as a national champion in the electromagnetic wire industry, the company is leveraging its advantages in the ultra-high voltage sector [14]. - **JianTou Energy (000600.SZ)**: The company reported a substantial increase in net profit by 169.37% in the first half of 2025, attributed to effective cost management and stable power generation performance [23][24]. Financial Performance - **Stone Technology**: The company’s H1 revenue reached 7.903 billion, with a net profit of 678 million, reflecting a significant year-on-year revenue increase [6]. - **Jiaocheng Ultrasonic**: The company’s H1 gross margin was 44.56%, with a net margin of 8.57%, indicating improved profitability [8]. - **Green's Harmonics**: The company’s Q2 revenue grew by 69.5%, with a net profit increase of 101% [15]. - **JianTou Energy**: The company’s H1 revenue was 111.13 billion, with a net profit of 8.97 billion, showcasing strong financial health [23]. Investment Recommendations - The report suggests a "Buy-A" rating for companies like Stone Technology and Jiaocheng Ultrasonic, indicating strong future growth potential [8][11]. - JianTou Energy is also recommended for investment due to its robust financial performance and strategic project developments [23][26].

Group 1 - The core viewpoint of the news highlights the performance and valuation of Yirui Technology, which closed at 110.0 yuan, marking a 1.84% increase, with a rolling PE ratio of 44.74, the lowest in 45 days, and a total market capitalization of 22.024 billion yuan [1] - Yirui Technology ranks 81st in the medical device industry, which has an average PE ratio of 59.49 and a median of 40.19 [1] - As of June 30, 2025, Yirui Technology had 6,990 shareholders, an increase of 1,245 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Yirui Technology's main business includes the research, production, sales, and service of digital X-ray detectors, high-voltage generators, combined ray sources, and tubes [1] - The latest financial results for the first half of 2025 show that the company achieved a revenue of 1.067 billion yuan, a year-on-year increase of 3.94%, and a net profit of 335 million yuan, a year-on-year increase of 8.82%, with a gross profit margin of 52.97% [1] - The PE ratios of other companies in the medical device industry vary, with the highest being 20.67 for Antu Biology and the lowest being 11.65 for Jiuan Medical [2]

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [6][12]. Core Insights - The company achieved a revenue of 1.067 billion yuan in H1 2025, representing a year-on-year increase of 3.94%, and a net profit attributable to shareholders of 335 million yuan, up 8.82% year-on-year [1]. - The company's gross margin was 52.97%, with a slight year-on-year decrease of 1.18 percentage points, while the net profit margin improved by 1.20 percentage points to 30.47% [2]. - The company is expected to benefit from the medical equipment upgrade policy, with projected revenues of 2.29 billion, 3.02 billion, and 3.83 billion yuan for 2025, 2026, and 2027 respectively, alongside net profits of 627 million, 851 million, and 1.053 billion yuan [4]. Financial Performance Summary - In H1 2025, the company's revenue from the detector business was 866 million yuan, a year-on-year increase of 2.65%, while the core components business generated 82 million yuan in revenue with a gross margin of 18.2% [2]. - The company invested 154 million yuan in R&D in H1 2025, representing a R&D expense ratio of 14.46% [2]. - The company forecasts a net profit growth rate of 34.9% for 2025, with an expected PE ratio of 34 [5][10].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% in the stock price within the next 6 to 12 months [16]. Core Viewpoints - The company has shown a recovery in performance with a 3.94% year-on-year increase in revenue for the first half of 2025, reaching 1.067 billion yuan, and an 8.82% increase in net profit attributable to shareholders, totaling 335 million yuan [4][5]. - The second quarter of 2025 saw a significant revenue growth of 9.32% year-on-year, amounting to 585 million yuan, alongside a 13.86% increase in net profit attributable to shareholders [4][5]. - The company is positioned as a leader in the domestic X-ray detector market, with a global market share of 19.83% projected for 2024, up from 16.46% in 2021 [11]. - The company is expanding its production capacity for silicon-based OLED backplanes and has received regulatory approval for a capital increase to fund new product development [12]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved a revenue of 1.067 billion yuan, with a net profit of 335 million yuan, reflecting a year-on-year growth of 3.94% and 8.82% respectively [4]. - The second quarter of 2025 reported a revenue of 585 million yuan, a 9.32% increase year-on-year, and a net profit of 191 million yuan, up 13.86% [4][5]. Growth Drivers - The recovery in revenue growth is attributed to several factors, including the domestic medical equipment replacement policy, partnerships with leading dental equipment manufacturers, and increased demand from lithium battery manufacturers [6]. - The company has seen significant growth in new core components and solutions, with some areas experiencing over 50% year-on-year growth [6]. Profitability Analysis - The gross profit margin for the second quarter of 2025 was 56.31%, an increase of 1.40 percentage points year-on-year, while the net profit margin rose to 32.36%, up 1.86 percentage points [7]. - The company’s operating cash flow showed a substantial recovery, with a net cash flow from operating activities of 818 million yuan, a year-on-year increase of 340.20% [8]. Research and Development - The company continues to invest in R&D, with expenses amounting to 154 million yuan in the first half of 2025, representing 14.46% of revenue [9]. - The company has filed 28 new intellectual property applications in the first half of 2025, including 14 invention patents [9]. Market Position and Expansion - The global X-ray core component market is expected to grow significantly, with projections indicating a market size exceeding 50 billion USD by 2030 [10]. - The company is expanding its production capacity for silicon-based OLED backplanes and has plans for new product development, which is expected to enhance its competitive edge [12].

Core Business Expansion and Competitiveness Enhancement - The company is a digital X-ray core component and comprehensive solution supplier, focusing on R&D, production, sales, and services of digital X-ray detectors, high-voltage generators, and other core components [1] - The company has established a global layout with six production bases, including new facilities in Haining, Taicang, and Cleveland, enhancing its competitive edge [1] - In the first half of 2025, overseas revenue reached 366 million yuan, accounting for approximately 34% of total revenue, indicating a continuous increase in overseas business [1] Investment in New Projects - The company plans to invest up to 1.8 billion yuan in a silicon-based OLED microdisplay backplane production project, which will add a capacity of 5,000 units per month [2] - This investment is expected to enhance the company's technological innovation and strengthen its core competitiveness [2] R&D Innovation and High-Quality Development - The company invested 154.24 million yuan in R&D, representing 14.46% of its revenue, and registered 70 new IPs, including 32 invention patents [2] - Ongoing projects include the development of key technologies for digital X-ray detectors and the establishment of an innovation base [2][3] Governance and Operational Standards - The company has established a governance structure with clear responsibilities among the shareholders' meeting, board of directors, supervisory board, and management [4] - The company held multiple board meetings and complied with legal and regulatory requirements for governance [5] Shareholder Returns and Value Sharing - In June 2025, the company completed its 2024 annual equity distribution, distributing cash dividends of 10 yuan per 10 shares and a stock bonus of 4 shares per 10 shares, totaling 142.89 million yuan in cash dividends [6] ESG Commitment and Sustainable Development - The company integrates ESG principles into its strategy and operations, focusing on innovation and quality management to contribute to human health [7] - A report detailing the company's practices in environmental protection and social responsibility is available on the Shanghai Stock Exchange website [7] Future Plans - The company will continue to focus on digital X-ray core components and solutions, enhance governance structures, and improve risk management to achieve high-quality development [8]

Company Overview - Yirui Technology's closing price on July 11 was 88.55 yuan, down 1.01%, with a rolling PE ratio of 37.80 times and a total market value of 17.729 billion yuan [1] - The company ranks 77th in the medical device industry, which has an average PE ratio of 52.06 times and a median of 37.22 times [1] - As of the first quarter of 2025, 47 institutions held shares in Yirui Technology, including 39 funds, with a total holding of 82.5452 million shares valued at 9.443 billion yuan [1] Business Operations - Yirui Technology focuses on the research, production, sales, and service of digital X-ray detectors, high-voltage generators, combination ray sources, and tubes [1] - The main product lines include the universal series, dental series, mammography series, radiotherapy series, industrial series, high-voltage generators, and combination ray sources [1] Financial Performance - In the first quarter of 2025, Yirui Technology reported revenue of 482 million yuan, a year-on-year decrease of 1.92%, while net profit was 143 million yuan, an increase of 2.74% [1] - The sales gross margin for the company was 48.92% [1]

Investment Rating - The report maintains a "Buy" rating for the company [6][20]. Core Views - The company is a leading global supplier of X-ray core components and solutions, with a diversified downstream distribution. The recovery in downstream medical, dental, and industrial sectors since 2025 is promising, and new products like CT tubes and silicon-based OLED microdisplay backplanes are expected to have significant growth potential [1][2]. - The company has announced an investment of up to RMB 1.8 billion for a silicon-based OLED microdisplay backplane production project, which is anticipated to add a capacity of 5,000 units per month [3][15]. - There is substantial domestic replacement potential for core components like CT tubes, with an estimated market space of RMB 1 to 5 billion due to the ongoing anti-dumping investigations against imports from the US and India [4][20]. Summary by Sections Financial Performance - The company expects a revenue decline of 2% in 2024, primarily due to poor downstream conditions, but anticipates a recovery in 2025 with a projected revenue increase of 17.18% [2][10]. - The forecasted net profit for 2025-2027 is RMB 5.9 billion, RMB 8.5 billion, and RMB 11.0 billion, representing year-on-year growth rates of 26%, 46%, and 29% respectively [5][19]. Revenue Breakdown - The detector segment is expected to grow at rates of 16%, 19%, and 19% from 2025 to 2027, with a recovery in demand from the medical and dental sectors [12][17]. - The core components segment is projected to see revenue growth of 43%, 39%, and 28% over the same period, driven by advancements in high-voltage generators and ray sources [13][17]. - The solutions and technical services segment is anticipated to grow significantly, with expected revenues of RMB 350 million, RMB 500 million, and RMB 700 million from 2025 to 2027 [14][17]. Valuation - The target price for the company is set at RMB 132, based on a price-to-earnings (PE) ratio of 45 times for 2025, reflecting a significant adjustment from previous estimates due to overall market conditions [5][20]. - The company's market capitalization is approximately RMB 17.36 billion, with a closing price of RMB 86.70 as of July 2, 2025 [7][10].

Group 1 - The core viewpoint of the news is that Yirui Technology's stock performance and financial metrics indicate a stable position within the medical device industry, despite a slight decline in revenue [1] - As of July 1, Yirui Technology's closing price was 88.5 yuan, with a PE ratio of 37.78 times and a total market capitalization of 17.719 billion yuan [1] - The average PE ratio for the medical device industry is 51.70 times, with a median of 37.36 times, positioning Yirui Technology at the 77th rank within the industry [1][2] Group 2 - Yirui Technology reported a revenue of 482 million yuan for Q1 2025, reflecting a year-on-year decrease of 1.92%, while net profit was 143 million yuan, showing a year-on-year increase of 2.74% [1] - The company's gross profit margin stands at 48.92% [1] - As of March 31, 2025, Yirui Technology had 5,745 shareholders, a decrease of 883 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

Group 1 - The core viewpoint of the news is that Yirui Technology's stock performance and financial metrics indicate a competitive position within the medical device industry, despite a slight decline in stock price and revenue [1] - As of June 26, Yirui Technology's closing price was 88.77 yuan, down 1.31%, with a rolling PE ratio of 37.90 times and a total market capitalization of 17.773 billion yuan [1] - The average PE ratio for the medical device industry is 49.45 times, with a median of 35.92 times, positioning Yirui Technology at the 80th rank within the industry [1][2] Group 2 - As of March 31, 2025, Yirui Technology had 5,745 shareholders, a decrease of 883 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of Yirui Technology includes the research, production, sales, and service of digital X-ray detectors, high-voltage generators, and other core components [1] - In the latest quarterly report for Q1 2025, Yirui Technology reported an operating income of 482 million yuan, a year-on-year decrease of 1.92%, and a net profit of 143 million yuan, a year-on-year increase of 2.74%, with a gross profit margin of 48.92% [1]